Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment

被引:6
|
作者
Hedestig, Oliver [1 ]
Sandman, Per-Olof [1 ]
Widmark, Anders [2 ]
Rasmussen, Birgit H. [1 ]
机构
[1] Umea Univ, Dept Nursing, S-90185 Umea, Sweden
[2] Umea Univ, Dept Radiat Sci, S-90185 Umea, Sweden
来源
关键词
D O I
10.1080/00365590701571530
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective. To illuminate the meanings of prostate-specific antigen (PSA) testing as narrated by men with localized prostate cancer (LPC) after primary treatment. Material and methods. Fifteen men were interviewed in their homes. The narrative interview text was analyzed using a phenomenological hermeneutic method inspired by the philosophy of Paul Ricoeur. Results. Life after treatment for LPC means feeling unsafe because of being affected by a life-threatening and unpredictable disease, characterized by a lack of early signs of progression. In this situation, PSA testing is ascribed as providing a sense of control to enable one to achieve a feeling of safety. Thus one meaning of PSA testing is receiving a message about the status of the body; another is a tense waiting related to fear of the results. A low, stable PSA value is interpreted as a sense of being safe based on confidence in the PSA tests and a sense of having control over the LPC via regular PSA testing. A rising value of the PSA blood test is understood as an indication of progression of the disease, but confidence in PSA testing also means that when the PSA value rises there is a sense of catching the cancer in good time. Conclusions. The comprehensive understanding of the meaning of PSA testing can be understood in terms of a lifeline to cling to when wondering whether the cancer is still in progress in the body or whether the treatment has been curative. This lifeline creates a feeling of security in a post-treatment life situation which is experienced as being unsafe.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 50 条
  • [41] Update on prostate-specific antigen testing for the early detection of prostate cancer
    Terrell, John D.
    Roehrborn, Claus G.
    Wians, Frank H., Jr.
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    [J]. LABMEDICINE, 2008, 39 (10): : 613 - 621
  • [42] Prostate-specific antigen testing for prostate cancer: the case for informed consent
    McCredie, M
    Cox, B
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (01) : 9 - 10
  • [43] Prostate-specific antigen testing for prostate cancer - Practical interpretation of values
    Randrup, E
    Baum, N
    [J]. POSTGRADUATE MEDICINE, 1996, 99 (02) : 227 - &
  • [44] Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer
    Hellerstedt, B
    [J]. UROLOGY, 2003, 62 (6B) : 79 - 86
  • [45] The performance characteristics of prostate-specific antigen and prostate-specific antigen density in tOChinese men
    Teoh, Jeremy Y. C.
    Yuen, Steffi K. K.
    Tsu, James H. L.
    Wong, Charles K. W.
    Ho, Brian S. H.
    Ng, Ada T. L.
    Ma, Wai-Kit
    Ho, Kwan-Lun
    Yiu, Ming-Kwong
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (01) : 113 - 116
  • [46] Prostate cancer and prostate-specific antigen testing in New South Wales
    Smith, David P.
    Supramaniam, Rajah
    Marshall, Villis R.
    Armstrong, Bruce K.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2008, 189 (06) : 315 - 318
  • [47] Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
    Spratt, Daniel E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (18)
  • [48] CONTEXTUAL ANALYSIS OF THE EFFECT OF PROSTATE-SPECIFIC ANTIGEN TESTING ON PROSTATE CANCER OUTCOMES AMONG ELDERLY MEN
    Jayasekera, J.
    Onukwugha, E.
    Tom, S.
    Harrington, D.
    Pradel, F. G.
    Naslund, M.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A98 - A98
  • [49] Complexed prostate-specific antigen, and complext prostate-specific antigen indices for early detection of prostate cancer in men with total prostate-specific antigen between 2.0 and 4.0 ng/ml
    Reissigl, A
    Remzi, M
    Wiunig, C
    Zlotta, A
    Ravery, V
    Hammerer, P
    Dobronski, P
    Kaisary, A
    Marberger, M
    Djavan, B
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04): : 426 - 427
  • [50] Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer
    Morote, J
    Trilla, E
    Esquena, S
    Serrallach, F
    Abascal, JM
    H'Mammed, YI
    de Torres, IM
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (04): : 239 - 243